NEW ORLEANS, Aug. 18, 2017 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO).
In May to July of 2016, patient deaths were reported in relation to the Phase 2 trial of Juno's immunotherapy treatment drug candidate, JCAR015. On July 7, 2016, Juno revealed that the FDA had issued a clinical hold on the trial following two patient deaths the prior week, but the Company placed the blame on another cancer drug, fludarabine, also used in the trial regimen. In November 2016, it was revealed that the FDA had suspended the JCAR015 trial and on March 1, 2017, the Company announced it was ending the drug trial.
Thereafter, Juno and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws.
KSF's investigation is focusing on whether Juno's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Juno shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.